In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Perrigo Company plc (PRGO), with a price target of $107. The company’s shares opened today at $57.93, close to its 52-week low of $57.22.
Chen commented:
“We rate PRGO as OW with a 12-month price target of $107. We think the company’s growth prospects and earnings potential are underappreciated. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $107. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $107.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 6.2% and a 35.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on Perrigo Company plc is a Hold with an average price target of $74.60.
See today’s analyst top recommended stocks >>
Perrigo Company plc’s market cap is currently $7.95B and has a P/E ratio of 68.14. The company has a Price to Book ratio of 1.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals.
